Blue Bees Therapeutics

📍 Orsay, France🗓 Founded 2022👥 9 employees💰 Last funded Oct 2025
Biotechnology
LinkedIn
Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG).
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2022
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
2
Frequently asked questions
Who invested in Blue Bees Therapeutics?
Blue Bees Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Blue Bees Therapeutics last raise funding?
The most recent investment in Blue Bees Therapeutics recorded on gritt.io was in October 2025.
When was Blue Bees Therapeutics founded?
Blue Bees Therapeutics was founded in 2022.
What industry is Blue Bees Therapeutics in?
Blue Bees Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Blue Bees Therapeutics based?
Blue Bees Therapeutics is headquartered in Orsay, France.